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ABSTRACT 
Ruthenium (II) complexes of the type [Ru(S)2(K)]
2+, where S=1,10-phenanthroline and K=2-NO2-phenyl thiosemicarbazone (Compound 
R1) and 2-OH-phenyl thiosemicarbazone (Compound R2) were evaluated for broad antiviral activity testing against a variety of viruses 
including Varicella Zoster Virus, Herpes Simplex Virus-1&2, Vaccinia Virus and Cytomegalovirus. Cytotoxic evaluation of these 
compounds were investigated against human embryonic lung cells (HEL), human epithelial cells (HeLa), African green monkey kidney 
cells (Vero cells), Crandell-Rees feline kidney cells (CRFK) and Madin Darby canine kidney cells (MDCK) using MTS assay. Among 
the compounds tested, R1 showed inhibitory activity against cytomegalovirus (EC50: 7.3-11 µM), while R2 was found to show modest 
antiviral activity with EC50 values of 27 and 69 µM for feline corona virus and feline herpes virus, respectively. The ruthenium 
compound R1 showed more cytotoxic activity against HeLa (MCC: 4µM) and MDCK (CC50: 4.9 µM) cell lines than against HEL, Vero 
and CRFK cells (CC50 values of ≥ 100 µM). These results suggest that the test Ru(II) compounds might be the potential antiviral agents 
with good cytostatic potentiality to various cell cultures.  
Keywords: Ruthenium, Thiosemicarbazone, Antiviral, Cytotoxicity, MTS assay. 
 
1. INTRODUCTION 
 Viruses are the smallest infectious agents, consisting 
essentially of nucleic acid (either DNA or RNA) enclosed in a 
protein coat or capsid. They are obligate intracellular parasites and 
thus depend upon the host cell for their replication. Viral 
infections are very common and responsible for a variety of 
diseases ranging from the common cold to rabies and AIDS. In 
contrast to the enormous number of anti-bacterial drugs, much 
lesser effective antiviral drugs are available. One of the most 
important reasons for the lack of success in developing antiviral 
drugs is due to the nature of the viruses, which totally depend 
upon the host cell for their multiplication and survival. 
Accordingly many compounds that may cause the death of viruses 
are also very likely to injure the host cells that harbour them. 
Although several compounds have potent antiviral activity both in 
vitro and in vivo at present only a limited number of synthetic 
compounds and α-interferon have been approved by the FDA for 
antiviral therapy in humans [1]. 
 However, none of these drugs are without toxicities and 
hence there is a demand for new antiviral agents, which needs all 
possible approaches towards the development of new antiviral 
drugs for the therapy of viral infections for which at present no 
clinically useful drugs or vaccines are available. Research on 
drugs based on ruthenium complexes is a fast developing field in 
medicine, especially in the development of chemotherapeutic 
agents with minimal side effects and immunity to acquisition of 
drug resistance [2]. 
 One particular group of Schiff bases as chelating agents 
that have been investigated over the past decade are the 
thiosemicarbazones (TSCs). TSCs are potent inhibitors of the 
enzyme ribonucleotide reductase and are capable of impairing the 
DNA synthesis and repair [3]. Thiosemicarbazone derivatives 
have a great importance in chemistry and biology due to their 
antiprotozoal [4], antibacterial [5], antiviral [6], antifungal [7] and 
antineoplastic [8] activities. The more electrophilic ruthenium 
complexes are always less toxic than their corresponding ligands 
[9]. It has been observed that the presence of certain bulky groups 
at position N4 of the thiosemicarbazone moiety greatly enhances 
the activity [10]. The synthesis of ruthenium complexes with 
thiosemicarbazone ligands has been receiving considerable 
attention due to the pharmacological properties of both complexes 
and ligands [11]. The thiosemicarbazone ligands usually 
coordinate to ruthenium through oxygen, nitrogen and sulfur 
donor atoms in their (N, S) bidentate form [12]. 
 Many of the biological properties have been attributed to 
ruthenium complexes including anticancer activity [13-18], 
antinociceptive [19, 20], antioxidant [21, 22], antitubercular [23], 
antimalarial [24, 25] and antimicrobial activities [26, 27]. 
Ruthenium-based anticancer chemotherapies are making 
significant advances in clinical trials. For example, the two 
ruthenium (III) compounds namely, imidazolium [trans-
tetrachloro [1H-imidazole) (S-dimethylsulfoxide) ruthenate (III)] 
(NAMI-A) [28] and indazolium [trans-tetrachlorobis (1H-
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indazole) ruthenate (III)] (KP1019 or FFC14A) [29] as 
antimetastatic drugs have successfully completed Phase 1 clinical 
trials and are scheduled to enter Phase 2 trials in the near future.  
 The two ruthenium complexes of the type 
thiosemicarbazones (TSCs) with the general formula 
[Ru(S)2(K)]
2+, where S=1,10-phenanthroline and K=2-NO2-phenyl 
thiosemicarbazone (ptsz) and 2-OH-ptsz, have been studied for in 
vitro antiviral activity against various viruses including varicella 
zoster virus (VZV), herpes simplex virus-1 and-2 (HSV-1&2), 
vaccinia virus and cytomegalovirus (CMV) and cytotoxic activity 
against HEL, HeLa, Vero Cells, CRFK and MDCK cell lines 
using the MTT assay. 
 
2. EXPERIMENTAL SECTION 
 The ruthenium complexes R1 & R2 were prepared using the 
synthetic strategy described in Schemes 1-2. The synthesis began 
by preparation of ptsz ligands 2]. The next step was performed by 
commercially available ruthenium trichloride with 1,10-
phenanthrolene. The final ruthenium complexes were synthesized 
by treating [Ru(S)2Cl2] with phenyl thiosemicarbazone ligands to 
provide the corresponded ruthenium complexes Ru (1,10-
phenanthroline)2 (2-nitro phenyl thiosemicarbazone) Cl2 
(Compound R1) and Ru (1,10-phenanthroline)2 (2-hydroxy phenyl 
thiosemicarbazone) Cl2 (Compound R2).  
 
Scheme 1. Synthesis of Nitrogen & Sulphur bearing ligands. (34) 
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Scheme 2. Synthesis of Ruthenium Complexes (R1&R2), where S= 1, 10 
phenanthroline, K=2-NO2-ptsz/2-OH-ptsz, R1=Ru (1,10-phenanthroline)2 
(2-nitro phenyl thiosemicarbazone) Cl2, R2=Ru (1,10-phenanthroline)2 (2-
hydroxy phenyl thiosemicarbazone) Cl2 
2.1. Chemistry. 
2.1.1. Preparation of Complexes. 
 The solvents of AR grade were obtained from S.D Fine 
Chem., Mumbai, and E. Merck, Mumbai. The reagents (puriss 
grade) were obtained from Fluka and E. Merck. 
 Hydrated ruthenium trichloride was purchased from Loba 
Chemie, Mumbai, and used as received. UV-visible spectra were 
on a Jasco spectrophotometer. FTIR spectra were recorded in KBr 
powder on a Jasco V410 FTIR spectrometer by the diffuse 
reflectance technique. 1H-NMR spectra were measured in CDCl3 
and DMSO-d6 on a Bruker Ultraspec 500 MHz/AMX 400 
MHz/300 MHz spectrometer. FAB mass spectra were recorded on 
a JEOL JMS600 spectrum with mNBA matrix.  
2.1.2. Preparation of substituted phenyl thiosemicarbazones 
(R-ptsz) 3] (Scheme-1). 
 A mixture of substituted benzaldehyde (1 mmol) and 
thiosemicarbazide (1 mmol) in 100 mL of ethanol was refluxed for 
3hrs and left Cytotoxicity, MTS assay, overnight. The solid was 
filtered, dried and purified by recrystallization from alcohol. 
2-NO2-phenyl thiosemicarbazone (2-NO2-ptsz): 
 Yield 84%, M.P. 256-258ºC (lit.,256ºC). IR (KBr) cm-1: 
3417-3380 (NH2& N-H), 3136 (C-H), 2901 (C-H), 1370 (C=S). 
Calcd. for C8H8O2N4S: C, 42.85; H, 3.57; N, 25.00. Found C, 
42.69; H, 3.52; N, 24.94%.λmax nm (MeOH): 230, 307, 375. 1H-
NMR (DMSO-d6): δ= 10.36 (1H, s), 9.02 (1H, s), 8.04 (2H, d), 
7.83 (2H, d), 7.24 (2H, d, J= 8.6 Hz). 
2-OH-phenyl thiosemicarbazone (2-OH-ptsz): 
 Yield 56%, M.P. 234-235ºC (lit.,235ºC).  IR (KBr) cm-1: 
3500-3200 (O-H), 3469-3320 (NH2 & N-H), 3133 (C-H), 1610 (N-
H), 1328 (C=S). Calcd. for C8H9N3OS: C, 49.21; H, 4.64; N, 
21.52. Found C, 49.20; H, 4.62; N, 21.28%.λmax nm (MeOH): 
242, 321, 398. 1H-NMR (DMSO-d6): δ= 12.6 (1H, s), 11.24 (1H, 
s), 8.07 (1H, s), 7.99 (1H, s), 7.89 (1H, s, -OH), 7.73 (2H, d, J=8.6 
Hz), 6.95 (2H, d, J=8.6 Hz). 
2.1.3. Preparation of cis-[bis(S)dichlororuthenium(II)] cis-
[Ru(S)2Cl2] 
4] (Step-1). 
 RuCl3.H2O, 1g (2.5 mmol) and Ligand S (5 mmol) were 
refluxed in 50 mL DMF for 3hrs under nitrogen atmosphere. The 
reddish brown solution slowly turned purple and the product 
precipitated in the reaction mixture. The solution was cooled 
overnight at 0oC. A fine microcrystalline mass was filtered off. 
The residue was repeatedly washed with 30% LiCl solution and 
finally recrystallized. The product was dried and stored in a 
vacuum desiccator over P2O5 for further use (Yield 75%). 
2.1.4. Preparation of [Ru(S)2(K)Cl2] (Where S=1,10-
phenanthroline; K=2-NO2-ptsz, 2-OH-ptsz) (Step-2). 
 To the black microcrystalline cis-[bis(S)dichloroRu(II)] 
cis-[Ru(S)2Cl2] (2 mmol) excess of ligand (2-NO2-ptsz, 2-OH-
ptsz) (2.5 mmol) was added and refluxed in ethanol under nitrogen 
atmosphere. The initial colored solution slowly changed to 
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brownish orange at the end of the reaction, which was verified by 
TLC on silica plates. Then the excess of ethanol was distilled off 
and this solution was added onto silica gel (60-120 mesh). The 
product was purified by column chromatography by using silica 
gel as stationary phase and chloroform-methanol as mobile phase. 
Compound R1 [Ru(phen)2(2-NO2-ptsz)Cl2]: 
 Yield 44%, black crystals, IR (KBr) cm-1: 3417-3380 
(NH2&N-H), 3136 (C-H) 2958 (C-H), 1370 (C=S).  Calcd. for 
C32H24Cl2N8O2Ru1S1:  C, 50.79; H, 3.17; N, 14.81. Found C, 
50.65; H, 3.15; N, 14.73%.1H-NMR (DMSO-d6): δ ppm:  12.49 
(1H, s), 9.04 (1H, s),  8.58 (3H, t), 8.36 (d, J=4.9 Hz, 2H), 8.26 (d, 
J=8.4 Hz, 2H), 8.06 (3H, t), 8.01 (d, J=5.0 Hz, 2H), 7.96 (3H, m), 
7.74 (3H, t), 7.62 (d, 2H, NH2 ), 6.23 (2H, d). FAB-MS (m-NBA): 
756 [Ru(phen)2 (2-NO2-ptsz)]
2+(Cl2)
-; 685 [Ru(phen)2 (2-NO2-
ptsz)]2+; 505 [Ru(phen) (2-NO2-ptsz)]
2+; 462 [Ru(phen)2]  
Compound R2 [Ru(phen)2(2-OH-ptsz)Cl2]: 
 Yield 46%, black crystals, IR (KBr) cm-1: 3510-3200 (O-
H), 3402-3329 (NH2&N-H), 3036 (C-H), 1611 (N-H), 1328 
(C=S).  Calcd. for C32H25Cl2N7ORu1S1: C, 52.81; H, 3.43; N, 
13.48. Found C, 52.26; H, 3.39; N, 13.32%.1H-NMR (DMSO-d6): 
δ ppm: 10.02 (d, J=5.1 Hz, 1H), 9.03 (1H, s), 8.91 (d, J=4.9 Hz, 
1H), 8.84 (t, J=8.6 Hz, 2H), 8.63  (d, J=8.4 Hz, 1H), 8.49 (d, J=8.4 
Hz, 1H), 8.34-8.20 (6H, m), 8.15-8.08 (2H, m), 7.91 (d, J=5.0 Hz, 
1H), 7.81-7.75 (2H, m), 7.68-7.64 (s, 1H, O-H), 7.49-7.45 (1H, 
m), 6.91 (s, 2H, br, NH2), 6.73 (d, J=14.6 Hz, 2H), 6.13 (1H, s).  
FAB-MS (m-NBA): 727 [Ru(phen)2 (2-OH-ptsz)]
2+(Cl2); 656 
[Ru(phen)2 (2-OH-ptsz)]
2+; 475 [Ru(phen) (2-OH-ptsz)]2+; 462 
[Ru(phen)2]. 
2.2. Biological Activities. 
 Ruthenium compounds (R1&R2) were evaluated for their 
antiviral and cytostatic activity in HEL, HeLa, Vero, CRFK and 
MDCK cells according to well-established procedures 5].  
2.2.1. Antiviral assay. 
 Different cell types were seeded at a density of 5x10³ cells 
per well in 96-well cell culture plates in suitable medium. 
Following 24 hrs incubation at 37°C and 5% CO2, medium was 
removed and 5-fold serial dilutions of the test ruthenium 
compounds were added in a total volume of 100 μL, after which 
the virus inoculum was added to each well. This inoculum resulted 
in a greater than 90% destruction of the cell monolayer after 3-5 
days of incubation at 37°C depending on the nature of the virus. 
The cytopathicity was determined microscopically or in the 
presence of a MTS solution that was added to each well. 
Following two hours of incubation at 37°C, the optical density of 
each well was then read at 498 nm in a microplate reader to 
measure the reduction of the MTS dye by cellular dehydrogenases 
(20 µL MTS for 3hrs at 37ºC) into a water soluble colored 
formazan product. The 50% effective concentration (EC50) was 
defined as the concentration of compound of which 50% cell 
viability was protected from the virus-induced cytopathic effect 
(CPE). The results are shown in Tables 2-4. 
 
Table 2. Antiviral activity of ruthenium compounds against CMV, VZV, HSV, VV and VSV in HEL cell cultures. 
Compounds 
Effective concentration EC50 (µM)
a 
HEL cell cultures 
CMV VZV 
HSV-1 
(KOS) 
HSV-2 
(G) 
HSV-1 
KOS ACVr(TK-) 
Vaccinia 
virus 
Vesicular 
stomatitis 
AD-169 Davis TK+VZV TK-VZV 
R1 11 7.3 >20 >20 >20 >20 >20 >20 >20 
R2 >20 >100 >20 >100 >100 >100 >100 >100 >100 
Ganciclovir 7.9 7.9 - - 0.02 0.01 4 >100 >100 
Cidofovir 0.95 1.3 - - 2 1 0.9 22 >250 
Acyclovir - - 2.1 143 0.4 0.2 22 >250 >250 
Brivudin - - 0.019 104 0.04 112 50 4 >250 
aEffective concentration required to reduce virus-induced cytopathicity by 50%. 
CMV: Cytomegalovirus, VZV: Varicella-Zoster virus, HSV: Herpes simplex virus 
Table 3. Antiviral activity of ruthenium compounds in HeLa and Vero cell cultures. 
Compounds 
Effective concentration EC50 (µM)
a 
HeLa cell culture Verocell culture 
Vesicular 
stomatitis 
virus 
Coxsackie 
virus B4 
Respiratory 
syncytial 
virus 
Para-
influenza-3 
virus 
Reovirus-1 
Sindbis 
virus 
Coxsackie 
virus B4 
Punta 
Toro virus 
R1 >0.8 >0.8 >0.8 >20 >20 >20 >20 >20 
R2 >20 >20 >20 >20 >20 >20 >20 >20 
DS-5000 1 >100 0.8 >100 >100 >100 >100 >100 
(S)-DHPA >250 >250 >250 >250 >250 >250 >250 >250 
Ribavirin 4 112 4 85 146 >250 250 25 
aEffective concentration required to reduce virus-induced cytopathicity by 50%. 
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Table 4. Antiviral activity of ruthenium compounds against feline corona and feline herpes virus, and influenza viruses. 
Compounds 
Effective concentration EC50 (µM)
a 
CRFK cell culture MDCK cell culture 
Feline 
Corona 
Virus 
Feline 
Herpes 
Virus 
Influenza A virus (H1N1 
subtype) 
Influenza A virus (H3N2 
subtype) 
Influenza B virus 
Visual 
CPE score 
MTS 
Visual 
CPE score 
MTS 
Visual 
CPE score 
MTS 
R1 >100 >100 >4 >4 >4 >4 >4 >4 
R2 27 69 >100 >100 >100 >100 >100 >100 
HHA 4.2 11 - - - - - - 
UDA 1.6 1.2 - - - - - - 
Ganciclovir >100 1.4 - - - - - - 
Ribavirin - - 2 3.1 2 2.2 0.8 2.7 
Amantadine - - 5 3.2 0.9 0.8 >200 >200 
Rimantadine - - >200 >200 0.4 0.6 >200 >200 
 
2.2.2. Cytotoxic assay. 
 MDCK cells were seeded at a density of 5x103 cells per 
well of a 96-well plate in suitable media. Twenty four hours later, 
serial dilutions of the test ruthenium compounds were added. Cells 
were allowed to proliferate for 3 days at 37°C, after which the cell 
number was determined by means of the MTS method. The 50% 
cytostatic concentration (CC50) was defined as the compound 
concentration that inhibited the proliferation of exponentially 
growing cells by 50%. Results are shown in Table1. 
Table 1. Cytotoxicity of Ruthenium compounds. 
Compounds 
MCC(µM)a CC (µM)b 
HEL HeLa Vero CRFK MDCK 
R1 100 4 100 >100 4.9 
R2 ≥100 100 100 >100 >100 
Ganciclovir >350 - - >100 - 
Cidofovir >300 - - - - 
Brivudin >300 - - - - 
DS-5000 - >100 >100 - - 
(S)-DHPA - >250 >250 - - 
Ribavirin - >250 >250 - - 
HHA - - - >100 - 
UDA - - - 26.5 - 
Amantadine - - - - >200 
Oseltamivircarb
oxylate 
- - - - >100 
aMinimum cytotoxic concentration (MCC) that causes a microscopically detectable alteration of cell morphology. 
bCytostatic concentration (CC) required to reduce cell growth by 50%. 
HEL: Human Embryonic Lung cells, HeLa: Human epithelial cervix carcinoma cells, 
Vero: African green monkey kidney cells, CRFK: Crandell-Rees Feline Kidney cells, 
MDCK: Madin Darby Canine Kidney cells 
 
3. RESULTS SECTION 
 The compounds of the newly synthesized ruthenium 
complexes were confirmed by UV, FT-IR, 1H NMR, Mass 
spectroscopy and C, H, N analysis. In the UV spectra all the 
ruthenium complexes showed broad and intense visible bands 
between 340 and 510 nm due to metal to ligand charge transfer 
transition (MLCT). In the UV region the bands at 280 and 310 nm 
were assigned to 1,10-phenanthroline ligand –*charge transfer 
transitions. The IR spectras contained the absorption bands 
revealing the existence of the NH2, C=N, C=S gps. The 
1H-NMR 
spectra of the complex, [Ru(phen)2(2-NO2-ptsz]Cl2 showed 24 
resonance peaks ( 10.03-6.13). The mass spectra of the Complex 
R1 gave the anticipated molecular ion peak and main 
fragmentation peaks, which were in accordance with the title 
complexes.  
 Both antiviral activity and cytotoxicity were determined by 
means of microscopical reading or the MTS method. For each 
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compound, the 50% effective concentration (EC50) and the 
minimum cytotoxic concentration (MCC) or the 50% cytostatic 
concentration (CC50) were determined. Among the tested 
ruthenium compounds, R1 afforded more cytotoxic activity against 
HeLa (MCC of 4µM) and MDCK (CC50 of 4.9µM) cell lines than 
against HEL, Vero and CRFK cells, whereas compound R2 was 
found to show less toxicity to the above cells even at 
concentrations up to 100 µM. 
 The compounds were also tested for in vitro antiviral 
activity against CMV, VZV, (HSV-1and -2), influenza virus (A 
and B), feline corona virus and feline herpes virus, vesicular 
stomatitis, vaccinia virus, Coxsackie virus B4, respiratory 
syncytial virus, reovirus-1, Sindbis virus and Punta Toro virus in 
different cell cultures. From the obtained results it was found that 
the compound R1 afforded antiviral activity against both CMV 
strains in HEL cell cultures (EC50: 2.3-11 µM). In these assays, the 
anti-CMV activity of the established cidofovir (EC50: 0.95-1.3 
µM) and ganciclovir (EC50: 7.9 µM) was also determined. Thus, 
the R1 compound was about equally active against CMV as 
ganciclovir. The other viruses were not affected (minimal antiviral 
effective concentration 5-fold lower than the minimal cytotoxic 
concentration) by the R1 and R2 compounds, except compound R2 
that was also found to show a modest antiviral activity against 
feline corona and feline herpes virus with EC50 values of 27 and 69 
µM, respectively. It should, however, be noticed that compound 
R1 is more cytotoxic than ganciclovir and cidofovir, but may be 
the rational basis for further exploration of novel related 
derivatives. The results suggest that the test Ru(II) compounds 
might be the potential antiviral agents with moderate cytostatic 
potentiality to various cell cultures. 
 
4. CONCLUSIONS     
 The present study involves the synthesis of two Ruthenium 
complexes by reaction with RuCl3 with thiosemicarbazones. The 
complexes were purified by column chromatography and 
characterized by FT-IR, NMR and Mass spectra. The complexes 
were screened for antiviral activity against various stains of DNA 
and RNA viruses and exhibited moderate antiviral activity and 
compared with reference compounds. Among the two complexes, 
R1 could be a potential antiviral agent with good cytostatic 
potentiality to various cell cultures. 
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